Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40l (CD154)

American Journal of Transplantation

Volumn 2, Issue 7, 2002, Pages 609-617

  Hackstein, Holger ^a,b   Wang, Zhiliang ^a   Morelli, Adrian E ^a   Kaneko, Katsuhiko ^a   Takayama, Takuya ^a   Colvin, Bridget L ^a   Bein, Gregor ^b   Thomson, Angus W ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Bone marrow; CD154; Dendritic cell

Indexed keywords

ALLOGRAFT; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MATURATION; CHIMERA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT SURVIVAL; HEART GRAFT; HEMATOPOIETIC CELL; IMMUNOHISTOLOGY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CD40 LIGAND; FLOW CYTOMETRY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSION; LIGANDS; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036705450     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.20705.x     Document Type: Article

References (45)

1. Billingham RE, Brent L, Medawar PB. 'Actively aquired tolerance' of foreign cells. Nature 1953; 172: 603-606.
2. Wood ML, Monaco AP. The effect of timing of skin grafts on subsequent survival in ALS-treated, marrow-infused mice. Transplantation 1977; 23: 78-86.
3. Thomas JM, Carver FM, Foi-MB et al. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 1983; 36: 104-106.
4. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
5. Murase N, Starzl TE, Tanabe M et al. Variable chimerism, graft-versushost disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation 1995; 60: 158-171.
6. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
7. Barber WH, Diethelm AG, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ. Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients. Transplantation 1989; 47: 66-71.
8. Fontes P, Rao AS, Demetris AJ et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344: 151-155.
9. Shapiro R, Rao AS, Fontes P et al. Combined simultaneous kidney/ bone marrow transplantation. Transplantation 1995; 60: 1421-1425.
10. Sellers MT, Deierhoi MH, Curtis JJ et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation 2001; 71: 1681-1683.
11. Ciancio G, Miller J, García-Morales RO et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71: 827-835.
12. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med 2001; 52: 353-370.
13. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
14. Exner BG, Colson YL, Li H, Ildstad ST. In vivo depletion of host CD4+ and CD8+ cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning. Surgery 1997; 122: 221-227
15. Khanna A, Steptoe RJ, Antonysamy MA, Li W, Thomson AW. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. Transplantation 1998; 65: 479-485.
16. Nikolic B, Zhao G, Swenson K, Sykes M. A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT. Blood 2000; 96: 1166-1172.
17. Tomita Y, Nishimura Y, Harada N et al. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 1990; 145: 4026-4036.
18. Okano S, Eto M, Tomita Y et al. Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation. Transplantation 2001; 71: 447-456.
19. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-469.
20. Hackstein H, Morelli AE, Thomson AW. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol 2001; 22: 437-442.
21. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001; 13: 323-335.
22. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to iduce anergic and regulatory T cells. Trends Immunol 2001; 22: 394-400.
23. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222.
24. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
25. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158: 5676-5684.
26. Hackstein H, Morelli AE, Larregina AT et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001; 166: 7053-7062.
27. Maraskovsky E, Brasel K,Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
28. Brasel K, McKenna HJ, Charrier K, Morrissey PJ. Williams DE, Lyman SD. Flt3 ligand synergizes with granulocyte-macrophage colonystimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997; 90: 3781-3788.
29. Morelli AE, Antonsamy MA, Takayama T et al. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus. J Immunol 2000; 165: 226-237.
30. Lu K, Li W, Fu F et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64: 1808-1815.
31. Hein J, Schellenberg U, Bein G, Hackstein H. Quantification of murine IFN-gamma mRNA and protein expression: impact of real-time kinetic RT-PCR using SYBR green I dye. Scand J Immunol 2001; 54: 285-291.
32. Fu F, Li Y, Qian S et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD8Odim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62: 659-665.
33. Okazaki H, Maki T, Wood M, Monaco AP. Effect of a single transfusion of donor-specific and nonspecific blood on skin allograft survival in mice. Transplantation 1980; 30: 421-424.
34. Markees TG, Phillips NE, Gordon EJ et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4 (+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446-2455.
35. Lutz MB, Suri RM, Niimi M et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30: 1813-1822.
36. van Kooten C, 8anchereau J. CD40-CD40 ligand. J Leukoc 8iol 2000; 67: 2-17.
37. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
38. Kirk AD, Blair PJ, Tadaki DK, Xu H, Harlan DM. The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci 2001; 356: 691-702.
39. Knechtle SJ. Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 2000; 12: 552-556.
40. Hussain MA. CD154 for the dragon: a promising development for pancreatic islet transplantation and cure for type 1 diabetes mellitus. Eur J Endocrinol 2000; 142: 111-113.
41. Markees TG, Phillips NE, Gordon EJ et al. Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Transplant Proc 1999; 31: 884-885.
42. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
43. Jones ND, Van Maurik A, Hara M et al. CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol 2000; 165: 1111-1118.
44. Guo Z, Meng L, Kim O et al. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway. Transplantation 2001; 71: 1351-1354.
45. Ito H, Kurtz J, Shaffer J, Sykes M. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 2970-2981.